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The short QT syndrome (SQTS) is a rare cardiac disorder associated with arrhythmias
and sudden death. Gain-of-function mutations to potassium channels mediating the
rapid delayed rectifier current, IKr, underlie SQTS variant 1 (SQT1), in which treatment
with Na+ and K+ channel blocking class Ia anti-arrhythmic agents has demonstrated
some efficacy. This study used computational modeling to gain mechanistic insights
into the actions of two such drugs, disopyramide and quinidine, in the setting of SQT1.
The O’Hara-Rudy (ORd) human ventricle model was modified to incorporate a Markov
chain formulation of IKr describing wild type (WT) and SQT1 mutant conditions. Effects
of multi-channel block by disopyramide and quinidine, including binding kinetics and
altered potency of IKr/hERG channel block in SQT1 and state-dependent block of sodium
channels, were simulated on action potential and multicellular tissue models. A one-
dimensional (1D) transmural ventricular strand model was used to assess prolongation
of the QT interval, effective refractory period (ERP), and re-entry wavelength (WL) by both
drugs. Dynamics of re-entrant excitation waves were investigated using a 3D human
left ventricular wedge model. In the setting of SQT1, disopyramide, and quinidine both
produced a dose-dependent prolongation in (i) the QT interval, which was primarily due
to IKr block, and (ii) the ERP, which was mediated by a synergistic combination of IKr
and INa block. Over the same range of concentrations quinidine was more effective in
restoring the QT interval, due to more potent block of IKr. Both drugs demonstrated an
anti-arrhythmic increase in the WL of re-entrant circuits. In the 3D wedge, disopyramide
and quinidine at clinically-relevant concentrations decreased the dominant frequency
of re-entrant excitations and exhibited anti-fibrillatory effects; preventing formation of
multiple, chaotic wavelets which developed in SQT1, and could terminate arrhythmias.
This computational modeling study provides novel insights into the clinical efficacy of
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disopyramide and quinidine in the setting of SQT1; it also dissects ionic mechanisms
underlying QT and ERP prolongation. Our findings show that both drugs demonstrate
efficacy in reversing the SQT1 phenotype, and indicate that disopyramide warrants
further investigation as an alternative to quinidine in the treatment of SQT1.
Keywords: arrhythmia, short QT syndrome, drug modeling, potassium channels, human ventricles, class 1a
anti-arrhythmics
INTRODUCTION
The short QT syndrome (SQTS) is a genetic condition in
which the QT interval on the ECG is abnormally short, leading
to increased risk of atrial and/or ventricular arrhythmias and
sudden cardiac death (SCD; Schimpf et al., 2005). The SQTS is
genetically heterogeneous, with a complex genotype-phenotype
relationship (Harrell et al., 2015). The first identified form of the
SQTS (SQT1) was caused by a missense mutation (N588K) to
the human Ether-à-go-go-Related Gene (hERG) encoding the α
subunit of channels carrying the rapid delayed rectifier potassium
current, IKr (Brugada et al., 2004). At physiological temperature,
the N588K-hERG mutation has been shown to significantly
attenuate inactivation, without altering the voltage dependence
of activation (McPate et al., 2005), causing a “gain-of-function”
in IKr which significantly reduces the QT interval (QTc≤ 300ms;
Brugada et al., 2004).
The current frontline treatment for SQTS patients is use of
an implantable cardioverter-defibrillator (ICD) device, which
protects against sudden arrhythmic death (Giustetto et al.,
2006). However, T-wave oversensing, which leads to erroneous
identification of tachyarrhythmic events, can be an issue with
such devices, as T-waves often appear tall and peaked in
SQTS patients, necessitating device reprogramming (Schimpf
et al., 2005). Furthermore, ICDs are not particularly suited to
some pediatric patients (Villafañe et al., 2013), necessitating
the pursuance of alternative, pharmacological approaches. Data
on SQTS patients are comparatively sparse, due to the rarity
of the condition. However, several studies have reported on
the effectiveness of quinidine at restoring the QT interval and
ventricular effective refractory period (ERP) in the setting of the
SQTS (Gaita et al., 2004; Wolpert et al., 2005; Giustetto et al.,
2006; Hu et al., 2017), as well as on the lack of effect of other
hERG inhibitors such as sotalol, ibutilide, and flecainide (Gaita
et al., 2004; Giustetto et al., 2015). A few patient studies have also
shown that disopyramide has some efficacy in reversing the SQTS
phenotype (Schimpf et al., 2007; Mizobuchi et al., 2008; Giustetto
et al., 2011).
Detailed in vitro studies into the pharmacology of N588K-
hERG linked SQT1 (McPate et al., 2006, 2008) used whole-cell
patch clamp measurements of expressed IhERG at 37
◦C to assess
the blocking potency of several canonical hERG inhibitors on
N588K mutant hERG channels. In those studies disopyramide
emerged as a potential alternative to quinidine, which is more
commonly used in SQT1 (Gaita et al., 2004; Giustetto et al.,
2006; Hu et al., 2017), as the IC50 (half maximal inhibitory
concentration) was increased only 1.5-fold compared to wild type
(WT) hERG channels (compared to a 3.5-fold increase reported
for quinidine). The reason for the comparative effectiveness of
these two agents appears to be due to the fact that neither drug
strongly relies on hERG channel inactivation gating in order to
exert an inhibitory effect (McPate et al., 2006, 2008; Perrin et al.,
2008).
The underlying mechanisms by which combined ion channel
blocking actions of disopyramide and quinidine exert anti-
arrhythmic effects in the setting of SQT1 are not well understood.
Whereas, several studies have previously used computer models
to gain insights into QT interval shortening and pro-arrhythmic
effects of SQT1 mutant hERG channels in human ventricles
(Zhang and Hancox, 2004; Weiss et al., 2005; Adeniran
et al., 2011), significantly less is known about the mode
of action of pharmacological agents on human ventricular
electrophysiology in SQT1. A recent simulation study (Luo
et al., 2017) adopted a simplified “pore block” approach, with
one-dimensional (1D) and 2D tissue simulations, to investigate
effects of quinidine and disopyramide in the setting of SQT1,
but failed to replicate beneficial effects of disopyramide seen
in the clinical setting (Schimpf et al., 2007; Mizobuchi et al.,
2008; Giustetto et al., 2011). The present study was undertaken
to provide comprehensive information regarding the actions
of both quinidine and disopyramide in the setting of N588K-
linked SQT1, incorporating drug binding kinetics and 3D tissue
simulations.
METHODS
Model Development
The O’Hara-Rudy dynamic (ORd) model of the human
ventricular action potential (AP; O’Hara et al., 2011) was used
for simulations in this study, due to its extensive experimental
validation and ability to reproduce complex behaviors such as
early after depolarizations (EADs)—a crucial requirement when
simulating pharmacological agents which pose a torsadogenic
risk. An updated form of the ORd model described recently
(Mann et al., 2016) was used, as this configuration gave a QT
interval shortening which was more concordant with clinical
observations, and reproduced increased T wave amplitude
observed in the SQTS (Schimpf et al., 2005; Anttonen et al.,
2009). Furthermore, this allowed comparative investigations
with an updated form of the 2006 ten Tusscher et al. (TP)
model (ten Tusscher and Panfilov, 2006) in order to assess
model dependence of results (see Discussion and Supplementary
Material Section 1.3).
The ORd model was further modified by (i) replacing the
fast sodium current, INa, formulation with that of the Luo-
Rudy model (Luo and Rudy, 1994) to facilitate propagation
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in tissue (see Supplementary Material Section 1.3 for further
consideration of this point), and (ii) implementing a Markov
chain formulation of IKr. Rate transitions of the drug-free IKr
Markov model describing WT and the SQT1 mutant N588K
were updated from our previous study (Adeniran et al., 2011)
and validated using voltage and AP clamp experimental data
conducted at 37◦C (McPate et al., 2005, 2009) to better describe
kinetic changes accounting for impaired inactivation during the
time course of the AP. New fits to experimental data and kinetic
parameters are given in Figure S1 and Table S1, respectively.
As SQTS mutations are expressed heterozygously in vivo, we
constructed a heterozygous formulation (WT-N588K) consisting
of 50% WT and 50% N588K channels. This approach has been
adopted in a previous investigation of SQT1 (Loewe et al., 2014)
and the heterozygote formulation, which is used throughout the
study, is hereinafter referred to simply as the SQT1 condition.
Modeling Actions of Disopyramide and
Quinidine on hERG Channels
Disopyramide and quinidine are class Ia agents, i.e., drugs which
exert an anti-arrhythmic effect through block of the fast sodium
current as well as repolarizing K+ currents (Roden, 2014). In
order to simulate interactions between both drugs and the
hERG/IKr channel, the Markov chain model of IKr was extended
to include a drug-bound open and drug-bound inactivated state,
as described previously (Perrin et al., 2008), shown in Figure 1.
The formulation for IKr is given by:
IKr = gKrO (V − EKr) , (1)
dC1
dt
= βC2− αC1, (2)
dC2
dt
= αC1 + β1C3− (β + α1)C2, (3)
dC3
dt
= α1C2 + β2O+ µI − (β1 + 2α2)C3, (4)
dI
dt
= α2C3 + βiO+ lII
∗
−
(
µ+ αi + kI
)
I, (5)
dO
dt
= α2C3 + αiI + lAO
∗
−
(
β2 + βi + kA
)
O, (6)
dI∗
dt
= kI[D]I − lII
∗, (7)
dO∗
dt
= kA[D]O− lAO
∗, (8)
where gKr is the maximal channel conductance, O an open
state, I an inactivated state, C1, C2, and C3 are closed states,
O∗ and I∗ represent drug-bound open and inactivated states,
respectively, V is the transmembrane voltage, EKr is the K
+
reversal potential, kX and lX are binding and unbinding rate
constants for states of type X, respectively, and [D] is the drug
concentration. Rate transitions to drug-bound states describing
the concentration- and state-dependent block of hERG channels
by disopyramide and quinidine were based on prior recordings
from our laboratorymade at 37◦C (Paul et al., 2001, 2002). Details
of parameterization of the drug-bound Markov chain IKr model
to experimental data are given in the Supplementary Material,
and parameters are detailed in Table S2.
Modeling Actions of Disopyramide and
Quinidine on Sodium Channels
Both disopyramide and quinidine have been shown previously
to exhibit use dependent block of INa (Koumi et al., 1992),
with quinidine producing more potent tonic block (i.e., resting
and inactivated channel block) than disopyramide. Interactions
between both drugs and sodium channels were represented using
the guarded receptor formalism (Starmer et al., 1984), in which
drugs bind to ion channel conformations with constant affinity
but access to each binding site is “guarded” by the state of the
ion channel. Disopyramide and quinidine were assumed to bind
to activated, inactivated, and resting sodium channels based on
experimental evidence (Koumi et al., 1992), with the formulation
for INa given by:
INa = gNa
(
1− bA − bI − bR
)
m3hj (V − ENa) , (9)
dbA
dt
= kA [D]m
3hj
(
1− bA − bI − bR
)
− lAbA, (10)
dbI
dt
= kI [D]
(
1− hj
) (
1− bA − bI − bR
)
− lIbI , (11)
dbR
dt
= kR [D]
(
1−m3
)
hj
(
1− bA − bI − bR
)
− lRbR, (12)
where gNa is the maximal channel conductance, bA, bI, and
bR represent the fractional block of activated, inactivated, and
resting states, respectively, m is the activation gate, h and j
are the fast and slow inactivation gates of the sodium channel,
respectively, ENa is the Na
+ reversal potential, and all other
parameters retain their previous definitions. Model fits to
experimental data on the dose-dependence of tonic block and
development of use-dependent block are shown in Figure 2, and
drug binding parameters are given in Table S3. Parameterization
of all ion channel drug interaction models was performed
using a bounded Nelder-Mead simplex algorithm (Moreno
et al., 2016); more details are given in the Supplementary
Material.
Modeling Actions of Disopyramide and
Quinidine on Other Channels
In addition to INa and IKr block, disopyramide and quinidine
exert secondary, generally weaker actions on various other ion
channel currents; namely, the L-type calcium current, ICaL,
the transient outward potassium current, Ito, the slow delayed
rectifier potassium current, IKs, the inward rectifier potassium
current, IK1 (quinidine only), and the late sodium current, INaL
(quinidine only). For these other ionic substrates affected, simple
pore blocks were simulated based on published dose-response
curves. Within the framework of pore block theory (Brennan
et al., 2009), the maximal conductance gi of an ionic current type
i is modified in a concentration-dependent manner, such that
gi = gcontrol,i
1
1+ ([IC50]i/[D])
nH
, (13)
Frontiers in Physiology | www.frontiersin.org 3 October 2017 | Volume 8 | Article 759
Whittaker et al. Modeling Class Ia Antiarrhythmics in SQT1
FIGURE 1 | Disopyramide and quinidine interactions with hERG channels. (Ai) Drug-free and (Aii) drug-bound (additional states shown in green) Markov chain models
of IKr/hERG. Simulated (solid line) and experimental (points) mean fractional block by disopyramide (DISO) of IhERG tail currents following pulse protocol (shown inset)
(Bi), and dose-response curve under WT (blue) and SQT1 mutant N588K (red) conditions (Bii), where IC50 values are 10.77 and 15.77µM, respectively. Simulated
(solid line) and experimental (points) mean fractional block by quinidine (QUIN) of IhERG during pulse protocol (shown inset) (Ci), and dose-response curve under WT
(blue) and SQT1 mutant N588K (red) conditions (Cii), where IC50 values are 620 nm and 2.16µM, respectively. Experimental data at 37
◦C are taken from Paul et al.
(2001, 2002) and McPate et al. (2008). The light blue shaded area shown for reference in panels (Bii,Cii) corresponds to the concentration range of 1–10µM.
where gcontrol,i represents the maximal conductance of the i
channel in drug-free conditions and nH is the Hill coefficient.
IC50 values extracted from the literature for disopyramide and
quinidine are given in Table 1. Comparative IC50 values for block
of IKr and INa (tonic block) by both drugs are given in legends for
Figures 1, 2.
The therapeutic steady-state plasma levels of both
disopyramide and quinidine are reported to be ∼2–
5µg/ml (Roden and Woosley, 1983), which corresponds
to a concentration range of ∼6–15µM for both agents.
However, actual bioavailability in vivo is less than this due to
pharmacokinetic factors such as plasma protein binding. 1 and
2 µM of disopyramide and quinidine likely constitute realistic
maximal unbound concentrations (Sagawa et al., 1997). To
encompass likely total as well as unbound concentrations, we
elected to simulate effects of a wide range of concentrations of
both agents (0.2–20µM) at the single cell level, and a narrower
set of more “clinically-relevant” concentrations (1, 2, 5, 10µM)
at the tissue level (represented by light blue shaded regions on
dose-response curves in Figures 1, 2).
Tissue Simulations
The monodomain equation (Clayton et al., 2011) was used to
describe the propagation of APs in tissue:
∂V
∂t
= ∇(D∇V)−
Iion
Cm
, (14)
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FIGURE 2 | Disopyramide and quinidine interactions with sodium channels. (A) Simulated (solid lines) and experimental (points) tonic block of sodium channels by
disopyramide (DISO) and quinidine (QUIN), and (B) use-dependent block of sodium channels elicited using pulse protocol (n = 30 pulses) shown inset. Experimental
data are taken from Koumi et al. (1992), where tonic block IC50 values are 36 and 17µM for disopyramide and quinidine, respectively. The light blue shaded area
shown for reference in panel (A) corresponds to the concentration range of 1–10µM.
TABLE 1 | Secondary pharmacological effects of disopyramide and quinidine on
ion channels.
Disopyramide Quinidine
IC50 (µM) Source IC50 (µM) Source
ICaL 1036.7 Kramer et al., 2013 14.9 Zhang and Hancox,
2002
Ito 20.9 Hanada et al., 2003 21.8 Nenov et al., 1998
IKs 88.1 Satoh, 2000 44.0 Kang et al., 2001
IK1 – – 42.6 Nenov et al., 1998
INaL – – 12.0 Wu et al., 2008
A summary of half maximal inhibitory concentration values (IC50) extracted from the
literature.
where D is the diffusion coefficient tensor, Iion is the total ionic
current, and Cm is the membrane potential. Equation (14) was
solved numerically using a finite-difference PDE solver based
on the explicit forward Euler method, as described previously
(Whittaker et al., 2017). The pseudo-ECG (pECG) was calculated
according to (Plonsey and Barr, 2013), i.e.,
8
(
x
′
, y
′
, z′
)
=
∫
(−∇V) •
[
∇
1
r
]
d, (15)
r =
[(
x−x
′
)2
+
(
y− y
′
)2
+
(
z − z
′
)2] 12
, (16)
where 8 is a unipolar potential generated by the multicellular
tissue preparation, r is the distance between a source point (x,
y, z) and the coordinate of a virtual electrode (x
′
, y
′
, z
′
), and  is
the domain of integration.
Heterogeneous 1D Strand Model
A 1D transmural model of human ventricle comprising 25
endocardial (ENDO) cells, 35 mid-myocardial (MCELL) cells,
and 40 epicardial (EPI) cells was used, with a total length of
15mm as in our previous studies (Adeniran et al., 2011, 2017).
Conduction was isotropic, except for a five-fold decrease in D at
the border of theMCELL and EPI regions (Gima and Rudy, 2002;
Zhang and Hancox, 2004; Adeniran et al., 2011, 2017). Planar
waves were initiated by applying a stimulus at the endocardial
surface, which propagated transmurally along the fiber toward
the epicardial surface.
For the 1D pECG, the virtual electrode was placed 2.0 cm
away from the epicardial end of the fiber, and the end of the
T wave was defined as the intersection of the steepest portion
of the descending limb with the baseline (Gima and Rudy,
2002). As in our previous study of SQT1 (Adeniran et al., 2011),
the ENDO:EPI:MCELL ratio of IKr maximal conductance was
adjusted to 1.0:1.6:1.0, based on experimental measurements of
transmural hERG mRNA expression (Szabó et al., 2005). This
resulted in larger T wave amplitude in the SQT1 condition—a
hallmark of SQTS patients (Schimpf et al., 2005; Anttonen et al.,
2009).
Heterogeneous 3D Left Ventricular Wedge
Model
A 3D wedge model of the left ventricular free wall incorporating
fiber and sheet orientations taken from a DT-MRI scan of
a human heart (Benson et al., 2011) was used to assess
the anti-arrhythmic potential of disopyramide and quinidine
in the setting of re-entrant excitation waves in SQT1. The
tissue geometry is segmented into ENDO, EPI, and MCELL
regions as described previously (Benson et al., 2011), and is
shown in Figure S2. Further details regarding conductivities
and orthotropy ratio can be found in the Supplementary
Material. Re-entry was initiated using the phase distribution
method (Biktashev and Holden, 1998; Colman et al., 2017;
Whittaker et al., 2017), in which an artificial asymmetric
conduction pattern is created, which develops into a re-entrant
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FIGURE 3 | Single cell action potentials and current traces. (Ai) Endocardial action potential (AP) at 1Hz under WT (silver, dashed line), SQT1 (red, solid line), SQT1 +
5µM disopyramide (DISO) (blue, solid line), and SQT1 + 2µM quinidine (QUIN) (green, solid line) conditions. Corresponding current traces are shown for IKr (Aii), INa
(Aiii), and ICaL (Aiv). The degree of fractional block of IKr and INa is shown in (Av,Avi), respectively. The concentration dependence of the single cell AP duration at
90% repolarization (APD90) and maximum upstroke velocity (MUV) is shown in (Bi,Bii), respectively.
scroll wave. Multiple initial condition phase maps were used
(n = 6) for 3D re-entry simulations (see Figure S3). The
lifespan of re-entry was calculated based on time domain
signals taken from transmural APs. Frequency domain signals
were obtained through Fourier transform analysis of pECGs
and used to compute the dominant frequency (DF) based on
the largest peak in the power spectrum density, as described
previously (Whittaker et al., 2017). The virtual electrode for
recording the pECG was placed ∼3.0 cm away from the
center of the endocardial surface of the wedge, as illustrated in
Figure S6.
RESULTS
Single Cell Investigations
Figure 3A shows the actions of a representative concentration
of disopyramide and quinidine (5 and 2µM, respectively) on
an endocardial ventricular cell AP and current profiles in the
SQT1 condition at 1Hz (see section Methods for consideration
of concentrations used). It can be seen that both disopyramide
and quinidine prolonged the action potential duration (APD)
(Figure 3Ai; 238.3 and 289.5 ms upon application of 5µM
disopyramide and 2µM quinidine, respectively, vs. 195.3 ms
in the drug-free SQT1 condition) due to a considerable
reduction in IKr, which prolongs phase 3 repolarization
(Figure 3Aii). Both drugs reduced the AP overshoot potential
due to reduced INa (Figure 3Aiii), whereas only quinidine
exhibited an effect on ICaL at the concentrations shown
(Figure 3Aiv). Figures 3Av,Avi show the fractional block of
IKr and INa, respectively, during the AP. The fractional block
of IKr in the presence of quinidine was greater than that
of disopyramide, even though the concentration was lower,
as the IC50 for IKr block is roughly an order of magnitude
lower (McPate et al., 2008). As both drugs block sodium
channels with similar potencies (Koumi et al., 1992), 5µM
disopyramide produced a larger fractional block of INa than 2µM
quinidine.
Figure 3B shows the effects on the single cell APD and
maximum upstroke velocity (MUV) for 15 logarithmically-
spaced free concentrations of disopyramide and quinidine
(ranging from 0.2 to 20µM) in the SQT1 condition. It can
be seen in Figure 3Bi that both drugs prolonged the APD in
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FIGURE 4 | 1D transmural ventricular strand simulations. (A) Endocardial (solid line), mid-myocardial (dashed line), and epicardial (dotted line) action potentials (APs)
at 1Hz under WT, SQT1, SQT1 + 5µM disopyramide (DISO), and SQT1 + 2µM quinidine (QUIN) conditions (A). Corresponding pseudo ECGs (pECGs) are shown in
(B), with the WT pECG (shown in gray) superimposed under that of the SQT1 condition for comparison. The QT interval, effective refractory period (ERP), and maximal
transmural dispersion of repolarization (TDR) for WT, SQT1, and SQT1 + varying concentrations of disopyramide (DISO) and quinidine (QUIN) is shown in (Ci,Cii),
respectively. Note that the y axis scale for QT interval and ERP is different to that of TDR.
a dose-dependent manner, with quinidine prolonging the APD
to a greater extent than disopyramide. Both drugs also reduced
the single cell MUV in a dose-dependent manner (Figure 3Bii),
with quinidine producing a slightly larger reduction in MUV
across all concentrations investigated. Figure S4 shows the
effect of disopyramide and quinidine on the restitution of
the APD. Both drugs exhibited a degree of reverse frequency
dependence (i.e., larger prolongation of the APD at longer
cycle lengths) in the setting of SQT1, which was more
prominent for quinidine over the range of concentrations
tested.
1D Transmural Ventricular Strand
Investigations
The effects of 5µM disopyramide and 2µM quinidine on
coupled cell APs in a 1D strand tissue model and the
corresponding pECG waveforms can be seen in Figures 4A,B.
As observed with the results on the single cell APD, 2µM
quinidine produced a more marked prolongation of the QT
interval than did 5µM disopyramide in the SQT1 condition
(341 vs. 289 ms, compared to 241 ms in the drug-free
SQT1 condition). Figure 4B shows the effects of four different
concentrations of disopyramide and quinidine (1, 2, 5, 10µM) on
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TABLE 2 | A summary of effects of disopyramide and quinidine on tissue
properties at 1Hz.
QT (ms) ERP (ms) CV (cm/s) WL (mm)
Drug-free WT 350 345 60.3 208.1
SQT1 241 235 60.2 141.4
SQT1 + disopyramide 1µM 252 246 57.8 142.3
2µM 262 257 56.0 143.8
5µM 289 288 51.3 147.6
10µM 326 333 45.9 152.9
SQT1 + quinidine 1µM 305 299 56.2 168.2
2µM 341 337 52.9 178.4
5µM 401 402 46.4 186.5
10µM 451 481 40.3 194.0
Comparison of QT interval, effective refractory period (ERP), conduction velocity (CV),
and excitation wavelength (WL) in drug-free WT and SQT1 conditions, as well as upon
application of 4 different concentrations of disopyramide and quinidine in the setting of
SQT1.
the QT interval, ERP, and transmural dispersion of repolarization
(TDR) in the 1D strand at 1Hz (the concentration range of
1–10µM disopyramide/quinidine is shown on dose-response
curves in Figures 1, 2 by light blue shaded regions). Both drugs
caused a dose-dependent increase in the QT interval and ERP
(Figures 4Ci,Cii). In agreement with the single cell results,
prolongation of the QT interval and ERP was greater with
quinidine than with disopyramide. The maximal TDR, which
was higher in the SQT1 condition than WT, was not restored
by disopyramide, whereas a modest reduction was observed for
high concentrations of quinidine. Although, quinidine increased
the ERP to a greater extent than disopyramide, it also produced
a greater slowing of the conduction velocity (CV), which affects
the wavelength (WL) of re-entry, given by WL = CV × ERP.
Nonetheless, the WL was consistently prolonged to a greater
extent with quinidine than with disopyramide. A summary of
the effects of four different concentrations of disopyramide and
quinidine on the QT interval, ERP, CV, and WL at 1Hz is given
in Table 2.
Ionic Contributions to Drug Actions of
Disopyramide and Quinidine
We hypothesized that the QT interval prolonging effects of
disopyramide and quinidine in the setting of SQT1 were mainly
due to IKr block, as a “gain-of-function” in IKr is responsible for
the SQT1 phenotype. This would explain why quinidine prolongs
the APD and QT interval to a greater extent than disopyramide,
as it is a more potent inhibitor of the hERG channel (McPate
et al., 2006, 2008). In order to investigate this, we computed the
effects of both drugs on theQT interval and ERP for four different
concentrations (1, 2, 5, 10µM) with combined multi-channel
actions, as well as three different hypothetical scenarios: (i) IKr
block alone; (ii) INa block alone; and (iii) IKr + INa block only. A
summary of these investigations is given in Figure 5.
Disopyramide block of IKr alone produced a relatively large
increase in the QT interval and the ERP, whereas INa block
alone produced only a modest increase in the ERP and very
small increase in the QT interval (due to widening of the QRS
complex). The combination of IKr and INa block produced
a synergistic increase in the ERP, e.g., disopyramide block of
IKr and INa alone (10µM) prolonged the ERP by 29.8 and
7.2%, respectively, compared to 38.7% for combined IKr and
INa block. The combined effects of 10µM disopyramide on
IKr and INa accounted for 92.9 and 92.8% of QT interval and
ERP prolongation, respectively, compared with all multi-channel
actions, suggesting that disopyramide block of Ito and IKs played
only minor roles in prolonging the APD.
In the case of quinidine, IKr block alone accounted for
98.4% of the QT prolongation at a concentration of 1µM,
and 87.6% at 10µM. The effects of INa block alone were
comparatively minor, extending the QT interval by only 3.7% at
a concentration of 10µM. Prolongation of the ERP was slightly
more dependent on INa block than QT prolongation, with the
blocking actions of quinidine on INa accounting for 13.4% of total
ERP prolongation at 10µM.Unlike disopyramide, relative effects
of combined block of IKr and INa by quinidine were dependent
on the concentration. At low concentrations (1 and 2µM),
combined INa and IKr block produced greater prolongation of
the QT interval and ERP than combined multi-channel actions,
highlighting the role of L-type calcium and late sodium channel
block in counterbalancing IKr block at these concentrations. At
higher doses (5 and 10µM), combined multi-channel actions
produced a larger increase in the QT interval and ERP than
combined block of IKr and INa alone, as quinidine block of IKs
and IK1 also contributed to APD prolongation.
During simulated low-rate tachycardia (2Hz), the
contribution of INa block to total ERP prolongation at
10µM compared to 1Hz increased from 17.3 to 28.2% for
disopyramide, and 13.4 to 25.3% for quinidine (see Figure S5),
reflecting development of greater use dependent block of INa at
faster rates.
3D Left Ventricular Wedge Simulations
In order to characterize drug effects on re-entry dynamics in
the setting of SQT1, the effects of disopyramide and quinidine
(concentrations of 1, 2, and 5µM) on the DF and re-entrant
excitation wave dynamics in the 3D ventricular wedge were
quantified and compared to the drug-free SQT1 condition. In
the absence of pharmacologicalmodulation, initiated scroll waves
were generally unstable and eventually degenerated intomultiple,
regenerative wavelets, characteristic of ventricular fibrillation
(VF), as can be seen in representative Video S1. The average
computed DF in the drug-free condition was 6.32Hz, and re-
entrant activity sustained for the full 5.0 s in all simulations (n
= 6). Application of all concentrations of disopyramide tested
reduced the DF in a dose-dependent manner, whereas likelihood
of re-entry termination was not increased in a dose-dependent
way, typically only occurring within the 5.0 s simulation period
for concentrations of 1 and 2µM (average DF and lifespan are
summarized for all 3D simulations in Figure S6). An example
of arrhythmia termination can be seen in representative Video
S2, where addition of 1µM disopyramide reduced the re-entry
lifespan to ∼1.4 s, and reduced the complexity of the electrical
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FIGURE 5 | Individual ionic contributions of IKr and INa to QT interval and ERP prolongation by disopyramide and quinidine. The dose-dependent increase in the QT
interval (Ai,Bi) and effective refractory period (ERP) (Aii,Bii) is shown for disopyramide (DISO) (A) and quinidine (QUIN) (B) for the following scenarios: all combined
actions (blue), actions on INa only (red), actions on IKr only (purple), and combined actions on INa and IKr only (green). Simulations conducted at 1Hz.
excitation wave pattern (i.e., reducing multiple wavelets to a
single wave). At a concentration of 5µM disopyramide using
the same phase distribution initial conditions, the initiated
scroll wave settled into a persistent single rotating scroll wave,
characteristic of ventricular tachycardia (VT), as seen in Video
S3. The initiated scroll wave also meandered to a much smaller
extent, due to visibly slowed conduction through block of INa. A
summary of the averaged DF, lifespan of re-entry, and number
of non-sustained arrhythmias (NST) following application of
disopyramide and quinidine is given in Table 3.
Application of quinidine exerted a stronger inhibitory effect
on mutant IKr in the setting of SQT1 than disopyramide
at the same concentration, decreasing the DF to a larger
extent. Similarly to disopyramide, it demonstrated the ability
to terminate re-entrant excitations under certain conditions, as
shown for 1µM quinidine in representative Video S4, where
the lifespan was reduced to ∼4.8 s. Furthermore, it precluded
the formation of a persistent VF-like electrical pattern, with
initiated scroll waves typically settling into a slowly-rotating VT-
like pattern at a higher concentration of 5µMquinidine (e.g., see
Video S5). Examples of arrhythmia termination by disopyramide
and quinidine are given in Figure 6, which shows snapshots
of re-entry for 2µM disopyramide and quinidine alongside
the drug-free SQT1 condition. In addition, localized AP traces
extracted from the center of the 3D wedge, corresponding
fractional block of INa and IKr, and pECGs are shown. A
summary of all pECGs from 3D wedge simulations is given in
Figure S6, where it can be seen that in general the higher the
concentration of disopyramide or quinidine, the more organized
the waveform.
DISCUSSION
In this study we have characterized the effects of class Ia anti-
arrhythmic agents disopyramide and quinidine in the setting of
SQT1 using a hierarchy of virtual human ventricle models. This
study builds on previous in silico work which has focused on QT
interval shortening and arrhythmia substrates in the setting of
SQT1 (Zhang and Hancox, 2004; Weiss et al., 2005; Adeniran
et al., 2011), by using biophysically-detailed computational
models to investigate the mode of action of two pharmacological
agents which have demonstrated clinical effectiveness in partially
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TABLE 3 | A summary of effects of disopyramide and quinidine on 3D wedge
simulations.
DF (Hz) Lifespan
reentry (s)
DF (Hz) Lifespan
reentry (s)
SQT1 6.32 5.00
(NST = 0)
SQT1 6.32 5.00
(NST = 0)
+1µM DISO 5.99 4.00
(NST = 2)
+1µM QUIN 5.03 4.97
(NST = 1)
+2µM DISO 5.29 4.34
(NST = 2)
+2µM QUIN 4.39 3.83
(NST = 3)
+5µM DISO 4.26 5.00
(NST = 0)
+5µM QUIN 3.15 4.93
(NST = 1)
The averaged dominant frequency (DF) and lifespan of re-entrant excitation waves (NST
denotes number of non-sustained arrhythmias) in drug-free SQT1 conditions is shown, as
well as upon application of different concentrations of disopyramide (DISO) and quinidine
(QUIN). In all cases n = 6.
reversing the SQT1 phenotype (Gaita et al., 2004; Wolpert et al.,
2005; Schimpf et al., 2007; Giustetto et al., 2011).
Main Findings
Ourmajor findings are as follows. (1) In the setting of SQT1, both
drugs caused a dose-dependent increase in the QT interval and
ERP, and a dose-dependent decrease in the CV. Quinidine was
more effective at restoring the QT interval to normal levels than
disopyramide, due to more potent block of IKr. (2) Although,
disopyramide and quinidine exhibit multi-channel effects, only
IKr and INa block were required to considerably prolong the QT
interval and ERP. (3) Both drugs showed an anti-arrhythmic
increase in theWL required to accommodate a re-entrant circuit.
(4) Both drugs demonstrated a dose-dependent decrease in the
DF of re-entry in 3D ventricular wedge simulations, which
was greater for quinidine, whilst preventing the formation of
chaotic, fibrillatory behavior, and occasionally terminating re-
entrant waves. For patients who do not tolerate quinidine,
disopyramide may offer an alternative pharmacological approach
in SQT1. A schematic summary of the anti-arrhythmic effects of
disopyramide and quinidine is given in Figure 7.
Model Validation
Hu et al. reported the average corrected QT (QTc) interval in
probands with the N588K hERG mutation and affected relatives
(n = 16) to be 284.7 ± 16.7 ms (Hu et al., 2017), which is
significantly smaller than control QTc intervals, e.g., 405.7 ±
30.2 ms (n = 149) given in Anttonen et al. (2009). Using these
average QTc intervals as a guide, this corresponds to a reduction
of ∼30% in N588K-mediated SQT1. In our 1D transmural
human ventricle model, the SQT1 condition reduced the QT
interval by ∼31%, which agrees closely with this estimate from
clinical observations. Moreover, the computed pECG accurately
reproduced increased T wave amplitude in the setting of SQTS
(Schimpf et al., 2005). The QT prolongation computed over
the concentration range tested (1, 2, 5, 10µM) was compared
with a range of clinical measurements in Table S4, where good
agreement is generally seen for concentrations of 1–5µM.
Anti-Arrhythmic Drug Actions
At the single cell level, disopyramide and quinidine produced
a dose-dependent increase in the APD90 and decrease in the
MUV in the setting of SQT1. Both drugs also demonstrated
some ability to restore rate adaptation, which is largely reduced
in SQTS patients (Wolpert et al., 2005). In the multicellular
1D strand, a dose-dependent increase in the QT interval and
decrease in the CV was observed, both of which were greater
for quinidine. Reduced Na+ current which decreases CV also
reduces cellular excitability and can thus suppress ventricular
ectopic activity, which was one historic motivation for using
class Ia anti-arrhythmic agents (Roden, 2014). Prolongation of
the ERP and QT interval upon application of disopyramide and
quinidine indicates that both agents were able to partially reverse
the effects of SQT1, but not restore TDR to levels seen in the
WT condition. In the case of quinidine, this finding is consistent
with a previous study which showed inability of 10µMquinidine
to restore TDR in an experimental model of SQT1 (Patel and
Antzelevitch, 2008).
By isolating individual and combined contributions of
disopyramide and quinidine block of INa and IKr in the 1D
tissue model, we demonstrated that only IKr block was necessary
to considerably prolong the QT interval in the setting of
SQT1 at a normal pacing rate. Prolongation of the ERP also
relied heavily on IKr block, but increased synergistically when
combined with INa block. The contribution of INa block to
ERP prolongation increased further at a faster rate (2Hz), due
to greater development of use-dependent block of INa. These
findings suggest that combined multi-channel blocking effects
of disopyramide or quinidine on other ionic currents such as
ICaL, IKs, Ito, IK1, and INaL play only minor roles at therapeutic
concentrations. Our study also substantiates the notion that IKr
blockers which do not rely strongly on channel inactivation
for binding should be considered desirable candidates for
pharmacological treatment of N588K-mediated SQT1 (McPate
et al., 2006, 2008; Perrin et al., 2008).
In 3D wedge simulations we investigated the effects of
varying concentrations of disopyramide and quinidine on
re-entry dynamics, with several initial condition (n = 6)
scroll waves investigated (Figure S3). In the SQT1 condition,
the single initiated scroll wave generally degenerated into
multiple wavelets, consistent with clinical observations of VF
in SQT1 patients (Brugada et al., 2004; Hu et al., 2017).
Application of disopyramide and quinidine decreased the
DF, and prevented formation of persistent VF-like electrical
wave patterns; both effects which are anti-arrhythmic. A
summary of all 3D simulations is given in Figure S6, where
it can be seen from the pECGs that application of both
drugs generally favored the transition from polymorphic
VT/VF-like waveforms in the drug-free SQT1 condition, to
more organized monomorphic VT-like waveforms, especially
for higher concentrations. Although low concentrations of
disopyramide and quinidine (1 and 2µM) demonstrated some
efficacy in terminating re-entrant excitation waves, paradoxically
the higher concentration (5µM) was less effective, as it caused
greater slowing of the CV, which can facilitate the maintenance
of arrhythmias (Nattel, 1998). However, it should be emphasized
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FIGURE 6 | Representative snapshots of re-entry under SQT1 and pharmacological modulation conditions. The evolution of scroll waves following initiation of re-entry
for time t = 100, 200, 500, 1,000, 3,000, and 5,000 ms is shown for SQT1 (Ai), SQT1 + 2µM disopyramide (DISO) (Bi), and SQT1 + 2µM quinidine (QUIN) (Ci)
conditions from an epicardial aspect. In each case, localized AP excitations (Aii,Bii,Cii), corresponding fractional block of INa (red) and IKr (blue) (Aiii,Biii,Ciii), and
pseudo ECG traces (Aiv,Biv,Civ) are shown.
that we only investigated very short-term (5.0 s) re-entry
dynamics. Furthermore, we investigated only the effects of
pharmacological modulation on maintenance and not initiation
of scroll waves. It is relevant in this regard that the Na+
blocking actions of both drugs reduce cellular excitability,
meaning a stronger stimulus is required to initiate APs, and
the observed increase in re-entry WL increases the spatial
stimulus requirement to initiate re-entry (Adeniran et al.,
2011).
Potential Pro-Arrhythmic Drug Actions
The pro-arrhythmic potential of QT interval prolongation
through hERG channel block has been known for some
time (Nattel, 1998). Anti-arrhythmic agents may pose a
risk even in the absence of disease such as ischemia or
infarction (Nattel, 1998), which has resulted in a decline in
the use of class Ia anti-arrhythmic drugs in recent years
(Roden, 2014). In the absence of abbreviated repolarization,
both disopyramide and quinidine have been associated with
acquired long QT syndrome and the life-threatening ventricular
arrhythmia torsades de pointes (Roden and Woosley, 1983).
However, it has been suggested that the QT prolonging
effect of these drugs, which is an unwanted side effect
in treatment of conditions such as atrial arrhythmias, is
desirable in the setting of SQT1 (Dumaine and Antzelevitch,
2006).
In supplemental investigations we found that both
disopyramide and quinidine demonstrated reverse frequency
dependence (i.e., larger APD prolongation at slower pacing
frequencies), which had the effect of partially restoring
rate adaptation which is reduced to a large extent in SQT1
(Wolpert et al., 2005; see Figure S4). In addition, using a
slow pacing protocol (0.5Hz) in mid-myocardial cells, we
evaluated in the setting of SQT1 under variant parameter
combinations the likelihood of development of EADs, which
may be a mechanism for torsades de pointes (Weiss et al.,
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2010). We found that under normal conditions EADs were
more readily inducible by 5µM quinidine than disopyramide
due to more potent block of IKr. In the setting of SQT1,
development of EADs by quinidine was much less likely than
under WT conditions, occurring only in cases of significantly
reduced repolarization reserve or ICaL agonism. 5 µM of
disopyramide did not induce EADs under any parameter
combinations in SQT1 conditions. The results of these
simulations, summarized in Figures S7, S8, suggest that
neither drug poses a torsadogenic risk in the setting of SQT1
within the range of concentrations used in this study, especially
disopyramide. Moreover, these simulations provide some
indications about the concurrent use of other drugs with
disopyramide and quinidine in SQT1. For example, our results
suggest that use of disopyramide and quinidine in conjunction
with additional hERG channel blockers or calcium channel
agonists is contraindicated.
Comparison with Other Simulation Data
A recent study investigated effects of quinidine, disopyramide,
and E-4031 on SQT1 in human ventricle computer models by
implementing simple “pore block” theory (Luo et al., 2017).
Whilst the models were able to predict the clinical effectiveness
of quinidine in the setting of SQT1 (Wolpert et al., 2005), they
did not reproduce favorable effects of disopyramide observed
clinically (Schimpf et al., 2007; Giustetto et al., 2011). This is
potentially due to differences in the models used—that study
used the TP model (ten Tusscher and Panfilov, 2006) whereas
the present study utilized the ORd model (O’Hara et al., 2011).
In supplemental investigations, the degree of APD/QT interval
prolongation at 1Hz under application of disopyramide and
quinidine in both “original” and “optimized” forms of the ORd
and TP models (according to modifications detailed in Mann
et al., 2016) was assessed. We found that “optimized” forms of
the ORd and TPmodels showed convergent behavior (Figures S9,
S10), whereas the original TP model underestimated the relative
degree of disopyramide-induced APD/QT prolongation.
Another potential reason for the ineffectiveness of
disopyramide in the Luo et al. study is due to lack of
consideration of drug binding kinetics. In particular, the
simple “pore block” approach used for INa in that study did
not account for the use dependence of sodium channel block
(Koumi et al., 1992), rendering it simplistic for arrhythmia
simulations, and unable to recapitulate the increase in sodium
channel block by class I drugs at fast rates (Roden, 2014).
The importance of considering use-dependent block of INa
on modulation of the ERP at fast racing rates is highlighted
in Figure S11. The present study utilized drug binding kinetic
models for INa and IKr, which were shown to be the primary
determinants of QT interval and ERP prolongation, and
reproduced quantitatively QT prolongation observed with
disopyramide in SQT1 (Schimpf et al., 2007; Giustetto et al.,
2011) at clinically-relevant concentrations (see Table S4). Whilst
the present study did not incorporate drug binding kinetics for
all affected ion channel currents due to lack of experimental data,
it nonetheless represents a significant advance over the previous
simulation study (Luo et al., 2017).
FIGURE 7 | Schematic representation of anti-arrhythmic effects of
disopyramide and quinidine in the setting of SQT1. The upper panel shows
inhibition of INa and IKr as the principal mode of action of disopyramide and
quinidine. At the cellular level, this corresponds to reduced maximum upstroke
velocity (MUV), increased effective refractory period (ERP), action potential
duration (APD), and rate adaptation, which is summarized in the middle panel.
The lower panel shows consequent effects at the tissue level; reduced
excitability and therefore reduced conduction velocity (CV), and prolonged QT
interval, which translates to a reduction in the dominant frequency (DF) of
re-entrant excitation waves and favors transition from multiple wavelet
ventricular fibrillation (VF)- like wave patterns to single scroll wave re-entry
and/or arrhythmia termination.
Limitations
There are a few limitations to consider in interpreting the
results of this study. Firstly, IKr/hERG block aside, most of the
IC50 values from which the drug models were constructed were
recorded from non-human, mammalian species due to lack of
human experimental data. For the same reason, state-dependent
drug binding models for INa and IKr only were considered,
with simple pore blocks being used for other currents such as
Ito, IKs, and ICaL. In addition, the structure of the drug-bound
Markov model of IKr used (Perrin et al., 2008) did not include
binding to closed states, the possibility of which cannot entirely
be excluded, though both quindine and disopyramide are clearly
predominantly gated state-dependent drugs that require access to
the hERG channel pore to bind (Lees-Miller et al., 2000; El Harchi
et al., 2012).
The heterozygous WT-N588K formulation used throughout
the study is based on the simplifying assumption that SQT1
mutant IKr behaves in the same way as an equal mix
of homomeric WT and mutant channels. In reality, the
channel population may be more complex, with each channel
comprising both WT and SQT1 mutant hERG channel subunits.
Nevertheless, our “SQT1” formulation reproduced QT interval
shortening to an extent that was in agreement with clinical
measurements, as well as increased T wave amplitude which is
commonly observed in SQTS patients (Anttonen et al., 2009),
thereby supporting the approach adopted here.
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Finally, some care must be exercised in interpreting the
results from the 3D ventricle wedge geometry which, despite
offering advantages over previously-used simplified geometries
(Luo et al., 2017), excludes realistic boundaries and lacks features
such as a Purkinje fiber network which may play a role in
arrhythmogenesis.
CONCLUSIONS
This study used computational modeling to dissect ionic
mechanisms underlying QT prolongation and anti-arrhythmic
actions of disopyramide and quinidine on SQT1 in human
ventricles. Both drugs were shown to be effective inhibitors
of mutant hERG channels, and demonstrated efficacy in
partially reversing the SQT1 phenotype. Furthermore, both
disopyramide and quinidine exhibited anti-arrhythmic
effects in the 3D left ventricular wedge. These, along
with our EAD simulations, substantiate the notion that
drugs which can be life-threatening in the context of
normal repolarization can be life-saving in the context
of abbreviated repolarization (Dumaine and Antzelevitch,
2006). This study further establishes disopyramide as a
potential suitable alternative for SQT1 patients who do
not tolerate quinidine well, and provides new insights
into class Ia-mediated pharmacological treatments in
SQT1.
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